Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-08-12 08:25:48 - browse：5

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： 'Essentially witchcraft:' A former naturopath takes on the field

WSS

How to bring more disabled researchers into academia

Health care court cases: Humana, Sutter, Novant

Precocious puberty in girls comes with mental health risks

Study: Why relieving medical debt did not improve financial outcomes

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Sen. Paul opposes bill to ban Chinese biotechs

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Medical records are filled with copy

NEJM study link tiny plastics in blood vessels to heart problems

At least 13 dead in Texas as scorching temps continue

STAT Virtual Event: ASCO Recap, Live!

George Santos makes 1st court appearance after pleading not guilty to 13 counts

My daughter's legacy lives on through her writing, phage therapy

United colonoscopy coverage change 'may cost lives,' doctors say

Former medical device CEO who sold dummy, plastic parts convicted of fraud

hotspot

The problem with charging patients to message their doctors

Curing rare childhood diseases will falter unless Congress steps up

Amylyx ALS drug fails large clinical trial

NIH tests clinical research in primary care with $30 million program

Novo Nordisk obesity pill bests Wegovy in early trial

Air quality improving but still lags in Black, Hispanic communities

entertainment

leisure time

hotspot

explore